Scrutiny In Store For Hong Kong’s First Advanced Therapy Rules
New Bill To Be Introduced In Legislative Council On 30 October
Executive Summary
Requirements for advanced therapies in Hong Kong are being modeled on the EU regulatory regime.
You may also be interested in...
Hong Kong Looks To EU For New Advanced Therapy Rules
Hong Kong is consulting on proposals to include advanced therapies in its regulatory framework for pharmaceuticals.
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
Outlook Turns To Marketing Strategy After Scoring EU First For Ophthalmic Bevacizumab
Outlook Therapeutics’ intravitreally injected Lytenava has won the thumbs up from the European Medicines Agency. The company is assessing both direct commercialization of the product and partnering in Europe on a country-by-country basis.